Live Analyst Rating Changes 8325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Maxwell Skor
MS
Maxwell Skor
Morgan Stanley
Wall Street Analyst
★★★★☆
#381
on 13Foresight · ranked by our own returns
67%
Success Rate
+9.2%
Average Return
14 of 21 calls profitable · +1.7% vs benchmark
📈 Across the calls we could measure, roughly 67% of Maxwell Skor's ratings turned a profit when each position was held for 2 year — averaging +9.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

88 Buy 24 Hold 0 Sell
Maxwell's Stock Coverage 15 ratings · 2026-07-15
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
INSM
Insmed
 Jul 06, 2026 BUY Strong Buy
+56.4% avg upside
36 analysts
$212.00
92.50% Upside
 -1.3%
PHVS
Pharvaris
 Jun 25, 2026 BUY Strong Buy
+31.6% avg upside
14 analysts
$46.00
34.21% Upside
 +5.3%
TCRX
TScan Therapeutics
 Jun 22, 2026 HOLD Strong Buy
+807.2% avg upside
12 analysts
 — +23.7%
CYTK
Cytokinetics
 Jun 16, 2026 BUY Strong Buy
+7.2% avg upside
36 analysts
$103.00
26.22% Upside
 +12.8%
CRNX
Crinetics Pharmaceuticals
 Jun 15, 2026 BUY Buy
-9.9% avg upside
21 analysts
$80.00
4.49% Downside
 +139.0%
CRSP
Crispr Therapeutics AG
 Jun 11, 2026 HOLD Buy
+49.0% avg upside
41 analysts
$60.00
18.39% Upside
 -0.3%
AVIR
Atea Pharmaceuticals
 May 18, 2026 HOLD Buy
+38.5% avg upside
6 analysts
$6.00
28.13% Upside
 +20.5%
ASND
Ascendis Pharma
 May 18, 2026 BUY Strong Buy
+2.8% avg upside
24 analysts
$256.00
4.19% Downside
 +13.8%
BCYC
Bicycle Therapeutics
 May 18, 2026 HOLD Strong Buy
+473.2% avg upside
20 analysts
$12.00
180.34% Upside
 -3.1%
MNPR
Monopar Therapeutics Inc
 May 18, 2026 BUY Strong Buy
-2.8% avg upside
18 analysts
$115.00
7.48% Upside
 ·
SANA
Sana Biotechnology
 May 18, 2026 BUY Strong Buy
+176.6% avg upside
14 analysts
$12.00
231.48% Upside
 +16.6%
RARE
Ultragenyx Pharmaceutical
 May 06, 2026 BUY Strong Buy
+107.3% avg upside
36 analysts
$67.00
108.09% Upside
 +30.4%
ADAG
Adagene
 Aug 22, 2025 HOLD Strong Buy
+103.6% avg upside
8 analysts
 — +61.1%
IVVD
Invivyd
 Nov 20, 2024 BUY Buy
+915.5% avg upside
8 analysts
$3.55
347.13% Upside
 +8.1%
BRNS
Barinthus Biotherapeutics
 Sep 25, 2023 HOLD Strong Buy
+602.7% avg upside
5 analysts
$3.25
424.10% Upside
 -61.7%
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Maxwell Skor — Frequently Asked Questions
How accurate are Maxwell Skor's stock ratings?
Based on the calls 13Foresight could measure, about 71% of Maxwell's ratings were profitable over a one-year hold, with an average return of +19.5% per rating, or +14.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Maxwell ranked on 13Foresight?
Maxwell Skor is currently ranked #381 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Maxwell cover?
Maxwell most recently has ratings on INSM, PHVS, TCRX, CYTK, CRNX, CRSP, AVIR, ASND, BCYC, MNPR, SANA, RARE and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.